Recent studies have demonstrated the efficacy of simultaneously attenuating G9a and DNMT1 activity in several cancer types with independent pharmacological inhibitors of both targets, and with a novel G9a/DNMT1 dual inhibitor, CM‐272 [46, 47, 48]. Here, DNMT1 is linked to cancer.